Q-omics provides the consensus-scored IQUB profile across patient tissues and cancer cell-line models. IQUB expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IQUB is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, IQUB RNA expression shows 18,167 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where IQUB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IQUB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IQUB survival associations across molecular data types. IQUB RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IQUB RNA expression–survival associations across cancer types. High IQUB expression shows unfavorable associations in LIHC and LGG, but favorable associations in KIRC, ACC, ESCA and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IQUB RNA expression.
This table summarizes IQUB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for IQUB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IQUB shows lower tumor expression in KICH, LUAD, LUSC, THCA and KIRC and higher tumor expression in COAD. The KICH box plot shows higher IQUB RNA expression in normal versus tumor tissue (log2 FC = −2.099, t-test p < 0.001).
This table shows molecular features associated with IQUB in patient tissues and cancer cell lines. In patient samples, IQUB shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, IQUB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
